SCTX Insider Trading Activity and SEC Form 4 Filings
SCTX insider trading summary
Over the past 12 months, insiders at Scribe Therapeutics, Inc. (SCTX) reported 21 open-market purchases worth $183.9M by 14 insiders and no sales on SEC Form 4. Net insider buying was $183.9M.
Latest SCTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 28, 2026 | Avoro Ventures LLC | Director | Buy | $144K (7,905 @ $18.25) |
| Jul 28, 2026 | Avoro Capital Advisors LLC | Director | Buy | $144K (7,905 @ $18.25) |
| Jul 28, 2026 | Behzad Aghazadeh | Director | Buy | $144K (7,905 @ $18.25) |
| Jul 27, 2026 | AH Bio Fund III, L.P. | 10% Owner | Buy | $5.0M (333,333 @ $15.00) |
| Jul 27, 2026 | Carl L Gordon | Director | Buy | $15.0M (1,000,000 @ $15.00) |
| Jul 27, 2026 | AH Equity Partners Bio II, L.L.C. | 10% Owner | Buy | $5.0M (333,333 @ $15.00) |
| Jul 27, 2026 | Orbimed Advisors LLC | Director | Buy | $15.0M (1,000,000 @ $15.00) |
| Jul 27, 2026 | OrbiMed Capital GP VIII LLC | Director | Buy | $15.0M (1,000,000 @ $15.00) |
| Jul 27, 2026 | AH Bio Fund II, L.P. | Insider | Buy | $5.0M (333,333 @ $15.00) |
| Jul 27, 2026 | AH Equity Partners Bio III, L.L.C. | 10% Owner | Buy | $5.0M (333,333 @ $15.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.